219873-06-0

Basic information

• Product Name: 4-Cyano-2-fluorobenzyl alcohol
• Synonyms: Benzonitrile, 3-fluoro-4-(hydroxymethyl)- (9CI);3-Fluoro-4-(hydroxymethyl)benzonitrile;4-Cyano-2-fluorobenzyl alcohol;3-Fluoro-4-(hydroxyMethyl)-benzonitrile[4-cyano--2-fluorobenzyl alcohol;3-Fluoro-4-(hydroxymethyl)benzonitrile99+%;Benzonitrile, 3-fluoro-4-(hydroxymethyl)-
• CAS NO: 219873-06-0
• Molecular Formula: C₈H₆FNO
• Molecular Weight: 151.14
• Product Categories: HALIDE;ALDEHYDE
• Mol File: 219873-06-0.mol

Chemical Properties

• Melting Point: 63-68°C
• Boiling Point: 288.8°Cat760mmHg
• Flash Point: 128.5°C
• Appearance: /
• Density: 1.27 g/mL at 25 °C
• Vapor Pressure: 0.00106mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.51±0.10(Predicted)
• CAS DataBase Reference: 4-Cyano-2-fluorobenzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyano-2-fluorobenzyl alcohol(219873-06-0)
• EPA Substance Registry System: 4-Cyano-2-fluorobenzyl alcohol(219873-06-0)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• WGK Germany: 1
• Hazardous Substances Data: 219873-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyano-2-fluorobenzyl alcohol is used as an intermediate in the synthesis of various pharmaceuticals for its potential biological activities, contributing to the development of new drugs with therapeutic benefits.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Cyano-2-fluorobenzyl alcohol serves as a key intermediate, aiding in the production of agrochemicals designed to protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
4-Cyano-2-fluorobenzyl alcohol is utilized as a starting material for the synthesis of other organic compounds, highlighting its versatility and importance in organic chemistry for creating a wide range of chemical products.

InChI:InChI=1/C8H6FNO/c9-8-3-6(4-10)1-2-7(8)5-11/h1-3,11H,5H2

Upstream product

• 188582-62-9 4-bromo-2-fluorobenzyl alcohol 
• 164149-28-4 4-cyano-2-fluorobenzoic acid 
• 557-21-1 dicyanozinc 
• 175596-01-7 methyl 4-cyano-2-fluorobenzoate 
• 105942-10-7 3-fluoro-4-formylbenzonitrile 
• 219873-05-9 C₁₀H₈FNO₂ 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 133059-44-6 4-bromo-3-fluorobenzonitrile 
• 50-00-0 formaldehyd 
• 64248-62-0 3,4-Difluorobenzonitrile 

Downstream Products

• 105942-09-4 4-(bromomethyl)-3-fluorobenzonitrile 
• 105942-10-7 3-fluoro-4-formylbenzonitrile 
• 368426-24-8 3-fluoro-4-(azidomethyl)benzonitrile 
• 1094459-14-9 3-fluoro-N'-hydroxy-4-(hydroxymethyl)benzimidamide 
• 1514888-56-2 1-{2-fluoro-4-[5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl]-benzyl}-3-azetidine carboxylic acid 
• 1000512-15-1 (4-(aminomethyl)-2-fluorophenyl)methanol 

Relevant articles and documents

Preparation method of 4-cyano-2-fluorobenzyl alcohol

The invention discloses a preparation method of 4-cyano-2-fluorobenzyl alcohol, and belongs to the technical field of medical intermediates. 3, 4-difluorobenzonitrile is adopted as a raw material and reacts with potassium bromide in the presence of a phase transfer catalyst, or 3-fluoro-4-bromobenzaldehyde and hydroxylamine are subjected to a dehydration reaction to obtain 3-fluoro-4-bromobenzonitrile, and then the 3-fluoro-4-bromobenzonitrile is subjected to Grignard reagent exchange and reacts with paraformaldehyde to obtain the 4-cyano-2-fluorobenzyl alcohol. The method is safe and stable, the obtained product is easy to purify, and the method has potential industrial amplification prospects.

Piperidine compound and preparation method and medical application thereof

The invention discloses a piperidine compound shown as a formula (I) and a preparation method and medical application thereof, and particularly relates to a piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof and a preparation method and application of the piperidine USP7 inhibitor compound or pharmaceutically acceptable salt or ester or solvate thereof. The compound provided by the invention can inhibit the activity of USP7 enzyme, has very good selectivity and druggability, and can be used for preparing medicines for preventing or treating tumor diseases or virus infectious diseases.

3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS

The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF

1,6-Naphthyridine or 8-azaquinazoline derivatives (I) are new. 1,6-Naphthyridine or 8-azaquinazoline derivatives of formula (I) are new. D : N or CR 4>; R 4> : H, F, CF 3 or 1-4C alkyl; Ar : 5-R 5>-6-R 6>-2-methyl-4-oxo-4H-1-benzopyran-8-yl; 3-R 6>-4-R 8>-1-naphthyl optionally substituted with 1-3 of R 7>; 7-R 6>-8-R 8>-5-quinolinyl optionally substituted with 1-2 of R 7>; or 2-R 9>-3-R 10>-4-R 8>-5-R 6>-phenyl; R 5> : H, F, Cl, CN, NO 2, CF 3 or 1-4C alkyl; R 6> : H or F; R 7> : halo, 1-4C alkyl, CF 3, 1-4C alkoxy or OCF 3; R 8> : CN or NO 2; R 9> : H or halo; optionally fluorinated 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio of di(1-4C alkyl)amino; or phenyl optionally substituted with halo, 1-4C alkyl or CF 3; R 10> : H, halo or 1-4C alkyl; R 1> : optionally fluorinated 1-4C alkyl; R 2> : 1-6C alkyl optionally substituted with 3-7C cycloalkyl or F; or SO 2R 11>; R 11> : 1-6C alkyl, CF 3 or 3-7C cycloalkyl; or phenyl or heteroaryl optionally substituted with 1-2 of halo, CN, 1-4C alkyl, CF 3, 1-4C alkoxy and/or OCF 3; R 3> : H, F, CF 3 or 1-4C alkyl. An independent claim is also included for a process for preparing (I). [Image] ACTIVITY : Hypotensive; Cardiant; Hepatotropic; Nephrotropic; Cerebroprotective. MECHANISM OF ACTION : Mineralocorticoid receptor (MR) antagonist. 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2-methyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide had an IC 50 of 35 nM when tested on cells expressing a GAL4-MR chimera.

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

A synthesis of the γ-secretase inhibitor BMS-708163

A concise, convergent racemic synthesis of BMS-708163 is reported. Two fragments consisting of N-4chlorophenylsulfonyl-3,3,3-trifluorpropylglycine and a 1,2,4-oxadiazole derivative of 2-fluorobenzyl alcohol were prepared in separate pots and then coupled

SUBSTITUTED 4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINES AND USE THEREOF

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridines, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

SUBSTITUTED-4-ARYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINAMIDES AND USE THEREOF

The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or pharmaceutically acceptable salts thereof, wherein Q is [INSERT CHEMICAL STRUCTURE HERE] or [INSERT CHEMICAL STRUCTURE HERE]; R1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula I, [Chemical formula should be inserted here. Please see paper copy] wherein R1 to R4 , R41 to R46 and Z have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias